Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,General Medicine
Reference29 articles.
1. Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E (2022) SGLT-2 Inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci 23(6):3107
2. Behrendt CA, Heidemann F, Rieß HC, Stoberock K, Debus SE (2017) Registry and health insurance claims data in vascular research and quality improvement. Vasa 46(1):11–15
3. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB (2012) Validating the adapted diabetes complications severity index in claims data. Am J Manag Care 18:721–726
4. Chen TS, Yu TS, Lin CL, Hsu CY, Hu WS (2023) Role of sodium-glucose cotransporter-2 inhibitors in risk of chronic kidney disease among patients with type 2 diabetes mellitus. J Nephrol 36(3):713–718
5. Costantini E, Carlin M, Porta M, Brizzi MF (2021) Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence. Acta Diabetol 58(9):1139–1151